Novel Small Molecules in IBD: Current State and Future Perspectives
Author:
Affiliation:
1. Department of Medicine 1, University Erlangen-Nürnberg, 91054 Erlangen, Germany
2. Deutsches Zentrum Immuntherapie (DZI), 91054 Erlangen, Germany
3. Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany
Abstract
Funder
German Research Foundation
Publisher
MDPI AG
Subject
General Medicine
Link
https://www.mdpi.com/2073-4409/12/13/1730/pdf
Reference54 articles.
1. Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More;Schreiner;Inflamm. Intest. Dis.,2019
2. Infliximab for induction and maintenance therapy for ulcerative colitis;Rutgeerts;N. Engl. J. Med.,2005
3. Manteniance infliximab in Crohn’s disease: The ACCENT I randomised trial;Hanauer;Lancet,2002
4. New agents for immunosuppression;Jefremow;Best Pract. Res. Clin. Gastroenterol.,2021
5. The endoscopic diagnosis of mucosal healing and deep remission in inflammatory bowel disease;Moriichi;Dig. Endosc.,2021
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Precision medicine in inflammatory bowel diseases;Intestinal Research;2024-01-31
2. Reproductive Safety Issues of Novel Small Molecules for the Treatment of Inflammatory Bowel Disease: A Systematic Review;Journal of Clinical Medicine;2023-12-20
3. Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years;Pharmaceuticals;2023-09-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3